Subtitled -- Peter Weyland - Promotheus Speech - TED - 2023
TED 2023 Speech -- subtitled courtesy of Per Jacobsen engineeredreality.wordpress.com Peter Weyland has been a magnet for controversy since he announced his intent to build the first convincingly humanoid robotic system by the end of the decade. Whether challenging the ethical boundaries of medicine with nanotechnology or going toe to toe with the Vatican itself on the issue of gene-therapy sterilization, Sir Peter prides himself on his motto, "If we can, we must." After a three year media blackout, Weyland has finally emerged to reveal where he #39;s heading next. Wherever that may be, we will most certainly want to follow.From:Per JacobsenViews:14 0ratingsTime:03:09More inFilm Animation

Link:
Subtitled -- Peter Weyland - Promotheus Speech - TED - 2023 - Video

Recommendation and review posted by Bethany Smith

Gene Therapy and Synthetic Biology
How the relatively young field of synthetic biology is changing the older field of gene therapy. Produced by UIUC iGEM 2012From:iGEMHPCollaborationViews:13 0ratingsTime:06:05More inEducation

More:
Gene Therapy and Synthetic Biology - Video

Recommendation and review posted by Bethany Smith

Healthier Humans or Designer Babies. Should scientists be playing GOD ?
Healthier Humans or Designer Babies. Should scientists be playing GOD ? It is a procedure that could prevent children from inheriting rare, incurable diseases such as stroke, blindness, deafness, kidney failure and heart disease. Healthy embryos are being created using two women and one man. Scientists are trying to eliminate defects that affect an estimated one in 4000 children. But it is stirring the ethics debate. There are a lot of questions about the morality of having babies with three parents, the implications for the child #39;s descendants, and the prospect of babies-to-order. The research for the new technique is being conducted at Oregon Health and Science University in the US. The procedure still needs US federal government approval to be tested on humans. In 2009, scientists were able to create eggs with DNA transplants from Rhesus monkeys. Four developed into healthy animals. The team has now used the same technique to create human embryos, with about half having abnormalities. But they say some 20 per cent of the eggs did produce embryos that would have been suitable for transfer back into the mother. So is science creating so-called designer babies? And should scientists be allowed to interfere with nature? To discuss this on Inside Story with presenter Zami Zeidan are guests: Josephine Quintavalle, the director of Core-ethics, a public interest group focusing on the ethics of human reproduction; Laurie Zoloth, a professor in biotechs and medical humanity at ...From:Tsiyonut timesViews:16 1ratingsTime:25:02More inNews Politics

Read the original:
Healthier Humans or Designer Babies. Should scientists be playing GOD ? - Video

Recommendation and review posted by Bethany Smith

Scientists reveal gene-swapping technique. Should scientists be playing GOD ?
Scientists reveal gene-swapping technique. Should scientists be playing GOD ? It is a procedure that could prevent children from inheriting rare, incurable diseases such as stroke, blindness, deafness, kidney failure and heart disease. Healthy embryos are being created using two women and one man. Scientists are trying to eliminate defects that affect an estimated one in 4000 children. But it is stirring the ethics debate. There are a lot of questions about the morality of having babies with three parents, the implications for the child #39;s descendants, and the prospect of babies-to-order. The research for the new technique is being conducted at Oregon Health and Science University in the US. The procedure still needs US federal government approval to be tested on humans. In 2009, scientists were able to create eggs with DNA transplants from Rhesus monkeys. Four developed into healthy animals. The team has now used the same technique to create human embryos, with about half having abnormalities. But they say some 20 per cent of the eggs did produce embryos that would have been suitable for transfer back into the mother. So is science creating so-called designer babies? And should scientists be allowed to interfere with nature? To discuss this on Inside Story with presenter Zami Zeidan are guests: Josephine Quintavalle, the director of Core-ethics, a public interest group focusing on the ethics of human reproduction; Laurie Zoloth, a professor in biotechs and medical ...From:Conspirafied0Views:49 0ratingsTime:25:02More inNews Politics

See the original post:
Scientists reveal gene-swapping technique. Should scientists be playing GOD ? - Video

Recommendation and review posted by Bethany Smith

27-Medical BiotechnologySG Part II.Gene Therapy, Tissue Engineering and Nanotechnology.mov
In theory, gene therapy offers a straight forward to the molecular treatment of various diseases, by using genes to prevent or treat disease by: Replacing a mutated gene(s) with a healthy copy; Inactivating/knocking out a mutated gene; or, Introducing new gene. Gene Therapy offers an approach to treating disease by either modifying the expressions of an individual #39;s genes or correction of abnormal genes. While this seems straight forward (ie replace or supply a healthy insulin gene in pancreatic cells of a diabetic) it has been difficult to actualize. Think here also about dual use problems (ie genetic doping for athletes, genetic modification enhancement for military personnel, and germline genetic engineering of humans with heritable genes). in this section we also review tissue engineering and some of the possibilities for nanotechnologies in medical devices. Nanosized GPS capable computers in our bloodstream?From:Albert KauschViews:5 0ratingsTime:37:43More inEducation

See the original post:
27-Medical BiotechnologySG Part II.Gene Therapy, Tissue Engineering and Nanotechnology.mov - Video

Recommendation and review posted by Bethany Smith

Researchers Test New Gene Therapy Method in Human Cells... And It Works
Researchers at the university #39;s Oregon National Primate Research Center and the OHSU Department of Obstetrics Gynecology have successfully demonstrated their procedure in human cells. It #39;s believed that this research, along with other efforts, will pave the way for future clinical trials in human subjects. Full report available at Scicasts via: s.scicasts.com [Video produced by Oregon Health Science University.]From:scicastsViews:9 0ratingsTime:03:46More inScience Technology

Excerpt from:
Researchers Test New Gene Therapy Method in Human Cells... And It Works - Video

Recommendation and review posted by Bethany Smith

Stopping the Clock
Original Article: Telomerase Gene Therapy in Adult and Old Mice Delays Aging and Increases Longevity Without Increasing Cancer Bernades de Jesus et al. EMBO Molecular Medicine, 2010. 4(8) p. 691-704. To view more exciting science videos visit http://www.yourekascience.comFrom:YourekaScienceViews:2 0ratingsTime:05:51More inScience Technology

View original post here:
Stopping the Clock - Video

Recommendation and review posted by Bethany Smith

Mixed results have been obtained from ground-breaking studies of a "three parent" method of preventing inherited mitochondrial diseases.

Scientists testing the technique, which involves switching DNA in a donor egg, successfully produced human embryos, but over half contained abnormalities.

Despite this, the US researchers said they had demonstrated a viable way of preventing a mother passing devastating diseases onto her offspring. The technique, known as maternal spinal transfer (MST), is one of the procedures that could be allowed following a landmark change in the law under consideration in the UK.

A public consultation is now under way on the proposal, which would effectively permit the creation of IVF babies with three genetic parents - a mother, a father and a donor.

[Related: Microsoft set to unveil Windows 8]

Mitochondria are rod-like structures in cells that have their own DNA - separate from that in the nucleus - and act as powerhouses, pumping out energy. Only mothers pass on mitochondrial genes to sons and daughters.

Defects in mitochondrial DNA (mDNA) give rise to a range of serious and potentially life-threatening diseases, including a form of muscular dystrophy, and conditions leading to hearing and vision loss, heart problems and intestinal disorders.

The aim of mitochondrial replacement is to prevent embryos being created with abnormal mitochondria, thereby breaking the chain of inherited disease.

MST is carried out before fertilisation. A spindle-shaped structure containing a mother's nuclear DNA is first removed from one of her eggs. This is transplanted into a healthy donor egg - with normal mitochondria - which has had its own spindle removed, and then fertilised by the intended father's sperm.

The developing embryo and baby now has cells containing nuclear DNA from both its parents, and healthy mitochondrial DNA from the donor.

Read the original post:
'Three parent' gene therapy results

Recommendation and review posted by Bethany Smith

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

bluebird bio, a leader in the development of innovative gene therapies for severe genetic disorders, announced today that the California Institute for Regenerative Medicine (CIRM) has approved an award to the company for $9.3 million for the first round of its new Strategic Partnership Awards initiative. The award is to support a Phase 1/2 study to evaluate the safety and efficacy of LentiGlobin, the companys development-stage program for the treatment of beta-thalassemia, which will be initiated in the United States in 2013.

We are very encouraged by the clinical data generated to date demonstrating the potential of LentiGlobin as a one-time transformative gene therapy for patients with beta-thalassemia, said David Davidson, M.D., chief medical officer, bluebird bio. bluebird bio has made significant advances in lentiviral vector design, transduction efficiency, and in our manufacturing process, enabling the production of gene-modified products that can be scaled and deployed for many different clinical indications. We are delighted that CIRM has chosen to recognize the importance of this innovative approach for the treatment of one of the most commonly inherited blood disorders, and we are excited to work with CIRM to continue the development of LentiGlobin in the U.S.

bluebird bios LentiGlobin product introduces a fully functional human beta-globin gene into the patient's own hematopoietic stem cells. These corrected stem cells ultimately produce fully functioning red blood cells. bluebird bio is currently conducting a Phase 1/2 trial examining the feasibility, safety and efficacy of LentiGlobin in the treatment of beta-thalassemia and sickle cell disease. Results of the first patient were reported in Nature in 2010, showing dramatic results, including stable expression of functional beta-globin resulting in transfusion independence which now extends for greater than four years following a single treatment.

This CIRM award is among the first awards under the agencys Strategic Partnership Awards initiative, which is designed to engage more effectively with industry and to increase outside investment in CIRM-funded stem cell research. The funding awards were made at the October 25, 2012 meeting of the stem cell agencys governing board, the Independent Citizens Oversight Committee (ICOC).

About CIRM

CIRM was established in November 2004 with the passage of Proposition 71, the California Stem Cell Research and Cures Act. The statewide ballot measure, which provided $3 billion in funding for stem cell research at California universities and research institutions, was overwhelmingly approved by voters, and called for the establishment of an entity to make grants and provide loans for stem cell research, research facilities, and other vital research opportunities. A list of grants and loans awarded to date may be seen here: http://www.cirm.ca.gov/for-researchers/researchfunding.

About bluebird bio

bluebird bio is developing innovative gene therapies for severe genetic disorders. At the heart of bluebird bios product creation efforts is its broadly applicable gene therapy platform for the development of novel treatments for diseases with few or no clinical options. The companys novel approach uses stem cells harvested from the patients own bone marrow into which a healthy version of the disease causing gene is inserted. bluebird bios approach represents a true paradigm shift in the treatment of severe genetic diseases by eliminating the potential complications associated with donor cell transplantation and potentially presenting a one-time transformative therapy using a patients own stem cells. bluebird bio has two later stage clinical products in development for childhood cerebral adrenoleukodystrophy (CCALD) and beta-thalassemia/sickle cell disease. Led by a world-class team, its operations are located in Cambridge, Mass., San Francisco and Paris, France. For more information, please visit http://www.bluebirdbio.com.

Read the original:
bluebird bio Awarded $9.3 Million From the California Institute for Regenerative Medicine to Further Gene Therapy ...

Recommendation and review posted by Bethany Smith

Newswise BOSTONAspirin therapy can extend the life of colorectal cancer patients whose tumors carry a mutation in a key gene, but has no effect on patients who lack the mutation, Dana-Farber Cancer Institute scientists report in the Oct. 25 issue of the New England Journal of Medicine.

In a study involving more than 900 patients with colorectal cancer, the researchers found that, for patients whose tumors harbored a mutation in the gene PIK3CA, aspirin use produced a sharp jump in survival: five years after diagnosis, 97 percent of those taking aspirin were still alive, compared to 74 percent of those not using aspirin. By contrast, aspirin had no impact on five-year survival rates among patients without a PIK3CA mutation.

Our results suggest that aspirin can be particularly effective in prolonging survival among patients whose colorectal cancer tests positive for a mutation in PIK3CA, said the studys senior author, Shuji Ogino, MD, PhD, of Dana-Farber, Brigham and Womens Hospital, and the Harvard School of Public Health. For the first time, we have a genetic marker that can help doctors determine which colorectal cancers are likely to respond to a particular therapy. He cautions that the results need to be replicated by other researchers before they can be considered definitive.

While aspirin is often prescribed for colorectal cancer patients, doctors havent been able to predict which patients will actually benefit from the treatment. The new finding suggests that the survival benefit is limited to the 20 percent whose tumors have the PIK3CA mutation.

For the remaining patients, aspirin may still be used, but it is likely to be much less effective and can sometimes lead to gastrointestinal ulcers and stomach bleeding.

The study was prompted by previous research that suggested that aspirin blocks an enzyme called PTGS2 (cyclooxygenase-2), causing a slowdown in the signaling activity of another enzyme, PI3K. That led researchers to hypothesize that aspirin could be especially effective against colorectal cancers in which the PIK3CA gene which provides a subunit of PI3K is mutated.

To conduct the study, investigators obtained data on 964 patients with rectal or colon cancer from the Nurses Health Study and the Health Professionals Follow-up Study long-term tracking studies of the health of tens of thousands of people. The data included information on the patients use of aspirin after diagnosis and the presence or absence of PIK3CA mutations in their tumor tissue.

The study, which combines the study of disease-related genes and research into large populations of individuals, represents a new, hybrid field which Ogino has termed molecular pathology epidemiology. The field may help us bring together information from two frontiers of cancer research at both the molecular and population levels in ways that are beneficial to patients, he said.

The study was supported in part by grants from the National Institutes of Health (P01 CA87969, P01 CA55075, P50 CA127003, R01 CA149222, R01 CA137178, and R01 CA151993); the Bennett Family Fund for Targeted Therapies Research; the Entertainment Industry Foundation through the National Colorectal Cancer Research Alliance; the Frank Knox Memorial Fellowship at Harvard University; and a Damon Runyon Clinical Investigator Award.

The lead author of the study is Xiaoyun Liao, MD, PhD, of Dana-Farber. In addition to Ogino, the papers other corresponding author is Andrew Chan, MD, MPH, of Brigham and Womens and Massachusetts General Hospital. Co-authors include Paul Lochhead, MB, ChB, Reiko Nishihara, PhD, Aya Kuchiba, PhD, Mai Yamauchi, PhD, Yu Imamura, MD, PhD, Zhi Rong Qian, MD, PhD, Ruifang Sun, and Jeffrey Meyerhardt, MD, MPH, of Dana-Farber; Charles Fuchs, MD, MPH, of Dana-Farber and Brigham and Womens Hospital; Edward Giovannucci, MD, MPH, of the Harvard School of Public Health and Brigham and Womens; Teppei Morikawa, MD, PhD, of University of Tokyo Hospital; Yoshifumi Baba, MD, PhD, of Kumamoto University, Japan; Kaori Shima, DDS, PhD, of Kagoshima University, Japan; and Katsuhiko Nosho, MD, PhD, of Sapporo Medical University, Japan.

Link:
Gene Mutation Identifies Colorectal Cancer Patients Who Live Longer with Aspirin Therapy

Recommendation and review posted by Bethany Smith

Researchers at Oregon Health & Science University say they have perfected a new gene therapy that could block the transmission of many inherited diseases from mother to child.

But the procedure could raise new ethical questions over genetically engineering offspring.

Already tested in monkeys, the technique replaces defective genetic material in a mother's egg cells before it is fertilized and implanted in the womb. In the new study, published in the journal Nature, researchers used 106 human egg cells obtained from volunteers.

If proven safe, the technique could be used to eliminate genetic dispositions toward diabetes, deafness and eye disorders, along with dementia, heart disease and neuropathy.

It would also give scientists the power to, for the first time, permanently alter the genetic material of future generations.

OHSU is already discussing the potential for human clinical trials with federal regulators, according to Shoukrat Mitalipov, the lead researcher.

Stay tuned for a fuller account later today.

-- Nick Budnick:

Twitter @nickbudnick

Read more:
Gene therapy procedure announced in Oregon could curb hereditary diseases, raise ethical questions

Recommendation and review posted by Bethany Smith

Public release date: 24-Oct-2012 [ | E-mail | Share ]

Contact: Jim Newman newmanj@ohsu.edu 503-494-8231 Oregon Health & Science University

PORTLAND, Ore. - Oregon Health & Science University's development of a new gene therapy method to prevent certain inherited diseases has reached a significant milestone. Researchers at the university's Oregon National Primate Research Center and the OHSU Department of Obstetrics & Gynecology have successfully demonstrated their procedure in human cells. It's believed that this research, along with other efforts, will pave the way for future clinical trials in human subjects.

The research results are online Wednesday, Oct. 24, in the highly respected journal Nature. Dr. Mitalipov also will present the results of his research at the American Society for Reproductive Medicine Conference in San Diego Oct. 24'.

The OHSU gene therapy method was initially devised through research in nonhuman primates led by Shoukhrat Mitalipov, Ph.D., associate scientist in the Division of Reproductive & Developmental Sciences at ONPRC, Oregon Stem Cell Center and OHSU School of Medicine departments of Obstetrics and Gynecology and Molecular and Medical Genetics.

The procedure was specifically developed to prevent diseases related to gene defects in the cell mitochondria. Mitalipov's previous work was published in the August 2009 edition of Nature. In the current study, Mitalipov, in collaboration with Paula Amato, M.D., associate professor of obstetrics and gynecology in the OHSU Center for Women's Health, demonstrated efficacy of this therapy in human gametes and embryos.

"Cell mitochondria contain genetic material just like the cell nucleus and these genes are passed from mother to infant," explained Mitalipov. "When certain mutations in mitochondrial DNA are present, a child can be born with severe conditions, including diabetes, deafness, eye disorders, gastrointestinal disorders, heart disease, dementia and several other neurological diseases. Because mitochondrial-based genetic diseases are passed from one generation to the next, the risk of disease is often quite clear. The goal of this research is to develop a therapy to prevent transmission of these disease-causing gene mutations."

To conduct this research, Mitalipov and his colleagues obtained 106 human egg cells from study volunteers recruited through OHSU's Division of Fertility and Reproductive Endocrinology. The researchers then used a method developed in previous nonhuman primate studies, to transfer the nucleus from one cell to another. In effect, the researchers "swapped out" the cell cytoplasm, which contains the mitochondria. The egg cells were then fertilized to determine whether the transfer was a success and whether the cells developed normally. Upon inspection, it was demonstrated that it was possible to successfully replace mitochondrial DNA using this method.

"Using this process, we have shown that mutated DNA from the mitochondria can be replaced with healthy copies in human cells," explained Mitalipov. "While the human cells in our study only allowed to develop to the embryonic stem cell stage, this research shows that this gene therapy method may well be a viable alternative for preventing devastating diseases passed from mother to infant."

The current Nature paper also expanded upon the previously reported nonhuman primate work by demonstrating that the method was possible using frozen egg cells. Mitochondria were replaced in a frozen/thawed monkey egg cell, resulting in the birth of a healthy baby monkey named Chrysta.

Read the original here:
OHSU researchers test new gene therapy method in human cells... and it works

Recommendation and review posted by Bethany Smith

ScienceDaily (Oct. 24, 2012) Oregon Health & Science University's development of a new gene therapy method to prevent certain inherited diseases has reached a significant milestone. Researchers at the university's Oregon National Primate Research Center and the OHSU Department of Obstetrics & Gynecology have successfully demonstrated their procedure in human cells. It's believed that this research, along with other efforts, will pave the way for future clinical trials in human subjects.

The research results are online Oct. 24, in the journal Nature. Dr. Mitalipov also will present the results of his research at the American Society for Reproductive Medicine Conference in San Diego Oct. 24

The OHSU gene therapy method was initially devised through research in nonhuman primates led by Shoukhrat Mitalipov, Ph.D., associate scientist in the Division of Reproductive & Developmental Sciences at ONPRC, Oregon Stem Cell Center and OHSU School of Medicine departments of Obstetrics and Gynecology and Molecular and Medical Genetics.

The procedure was specifically developed to prevent diseases related to gene defects in the cell mitochondria. Mitalipov's previous work was published in the August 2009 edition of Nature. In the current study, Mitalipov, in collaboration with Paula Amato, M.D., associate professor of obstetrics and gynecology in the OHSU Center for Women's Health, demonstrated efficacy of this therapy in human gametes and embryos.

"Cell mitochondria contain genetic material just like the cell nucleus and these genes are passed from mother to infant," explained Mitalipov. "When certain mutations in mitochondrial DNA are present, a child can be born with severe conditions, including diabetes, deafness, eye disorders, gastrointestinal disorders, heart disease, dementia and several other neurological diseases. Because mitochondrial-based genetic diseases are passed from one generation to the next, the risk of disease is often quite clear. The goal of this research is to develop a therapy to prevent transmission of these disease-causing gene mutations."

To conduct this research, Mitalipov and his colleagues obtained 106 human egg cells from study volunteers recruited through OHSU's Division of Fertility and Reproductive Endocrinology. The researchers then used a method developed in previous nonhuman primate studies, to transfer the nucleus from one cell to another. In effect, the researchers "swapped out" the cell cytoplasm, which contains the mitochondria. The egg cells were then fertilized to determine whether the transfer was a success and whether the cells developed normally. Upon inspection, it was demonstrated that it was possible to successfully replace mitochondrial DNA using this method.

"Using this process, we have shown that mutated DNA from the mitochondria can be replaced with healthy copies in human cells," explained Mitalipov. "While the human cells in our study were allowed to develop to the embryonic stem cell stage, this research shows that this gene therapy method may well be a viable alternative for preventing devastating diseases passed from mother to infant."

The current Nature paper also expanded upon the previously reported nonhuman primate work by demonstrating that the method was possible using frozen egg cells. Mitochondria were replaced in a frozen/thawed monkey egg cell, resulting in the birth of a healthy baby monkey named Chrysta.

The second portion of the study, which was completed at ONPRC, is also considered an important achievement because egg cells only remain viable for a short period of time after they are harvested from a donor. Therefore, for this therapy to be a viable option in the clinic, preservation through freezing likely is necessary so that both the donor cell and a mother's cell are viable at the time of the procedure.

While this form of therapy has yet to be approved in the United States, the United Kingdom is seriously considering its use for treating human patients at risk for mitochondria-based disease. It's believed that this most recent breakthrough, combined with earlier animal studies, will help inform that decision-making process.

Here is the original post:
New gene therapy method tested in human cells ... and it works, researchers report

Recommendation and review posted by Bethany Smith

PROSTATE CANCER and stem cells.wmv
ramirezdelrio.com Business entrepreneur Larry Howard #39;s 77 year old father was in deep trouble. He had been diagnosed with metastatic prostate cancer by his doctors at Kaiser Permanente. Their treatments had failed to check it and it was spreading. As-a-result the elder Howard had lost a great deal of weight and was running out of time. Larry had heard that a team of doctors in Mexico was using umbilical cord stem cells that had been genetically modified to fight cancer. One of the chief medical consultants to this program, in fact, was actually a friend of Larry #39;s; namely, pioneering physician and stem cell medicine expert David Steenblock. Larry took his father to see Dr. Steenblock, who sent them both to Mexico. The senior Mr. Howard was infused with the genetically engineered stem cells and wound up in total remission within 3 month #39;s time. He went on to regain all the weight he had lost previously and soon felt so good that he resumed socializing and dating. In this very short video segment Larry Howard shares how his father went from gravely ill to free of any detectable cancer.From:btancredi1Views:153 0ratingsTime:01:10More inScience Technology

Originally posted here:
PROSTATE CANCER and stem cells.wmv - Video

Recommendation and review posted by simmons

Stem Cell Update from Panama 3 Years Later
I had my first stem cell treatment for Multiple Sclerosis in November 2008. After much research and education, I decided to leave the US and go to Cell Medicine in Costa Rica at the time. 3 years later the clinic has grown and consolidated their lab and facilities to Panama City. The treatment wasn #39;t a cure, but it worked amazingly well for me and gave me a second chance at life. My MS is progressive and I will continue to turn to stem cells for ongoing treatment of my disease. Hopefully one day very soon with continuing discussions with Gov. Rick Perry and others, we will see stem cell treatments more widely available in the United States. iLoveMyNewStemCells!From:Holly HuberViews:1636 12ratingsTime:05:28More inPeople Blogs

Excerpt from:
Stem Cell Update from Panama 3 Years Later - Video

Recommendation and review posted by simmons

GeneCell International on Miami Moms
GeneCell International is one of the leaders in the field of stem cell banking. We operate a laboratory that focuses on processing and cryopreserving of stem cells derived from umbilical cord blood, dental pulp, adipose tissue, other tissues, and cells that can be cryogenically preserved. Our purpose is to provide families with the highest quality stem cell products and services and the best customer service, unparalleled scientific excellence and innovative leadership in the areas of stem cell collection, processing and cryopreservation. We are constantly updating our expertise in these disciplines so that individuals and their families can count on every available therapeutic option should a debilitating disease manifest itself. Our goal is to assist individuals around the world make the most of the advances in stem cell medicine.From:genecellintlViews:153 1ratingsTime:00:31More inEducation

Read more from the original source:
GeneCell International on Miami Moms - Video

Recommendation and review posted by simmons

RGO Walking
T-6 Asia A Complete Injury. March 4 2011 is the date of my injury. I have had 2 stem cell treatments at Cell Medicine Institute, Panama City, Panama.From:TheBncfilmsViews:853 2ratingsTime:02:41More inEntertainment

Excerpt from:
RGO Walking - Video

Recommendation and review posted by simmons

Walk
Some video of me doing water therapy at Lawrence County physical therapy Institute in New Castle Pennsylvania. I also do gait training at Harmerville rehab center. My name is Chris Niles. I #39;m a T6 Asia A complete spinal cord injury. I was injured March 4, 2011. I have had two treatments of adult stem cell therapy at Cell Medicine, located in Panama City, Panama. I have made significant gains since participating in stem cell therapy. Improvements with body temperature regulation, blood pressure, lower back muscle regeneration, nerve pain reduction. I Have sensory sensation down to about my T10 in my back. I am looking to go for my third treatment of adult stem cells in 2012.From:Chris NilesViews:542 2ratingsTime:04:27More inPeople Blogs

Read this article:
Walk - Video

Recommendation and review posted by simmons

Cord Blood Registry Helps Families Use Stem Cells
Learn more at http://www.cordblood.com CBR #39;s team of dedicated professionals is prepared to guide you through every step of the banking process and beyond. Meet Sherry, CBR #39;s transplant coordinator. As Sherry says, her employer is CBR, but she works for the families who need newborn stem cell medicine. She is the voice parents hear over the phone when they need to use their stored cord blood stem cells. Sherry #39;s dedication and passion to deliver exceptional customer service to clients is one example of the many people at Cord Blood Registry who are committed to helping families live longer, healthier lives.From:cordbloodregistryViews:250 7ratingsTime:01:25More inScience Technology

Continued here:
Cord Blood Registry Helps Families Use Stem Cells - Video

Recommendation and review posted by simmons

Cord Blood Registry #39;s Leading Science and Research Team
Learn more about cord blood stem cells here http://www.cordblood.com Cord Blood Registry #39;s Scientific and Medical Affairs team, led by Heather Brown Vice President of Scientific and Medical Affairs, is dedicated to helping understand, communicate and advance stem cell medicine. Her team #39;s focus is on helping find new uses for cord blood, including supporting research that is looking for treatments for conditions that have no treatment today. Our company was founded on the belief that saving newborn stem cells can change the future of medicine. Whether it #39;s providing newborn stem cell banking at no cost to a family with a medical need or partnering with world-class researchers for first-of-their-kind clinical trials, we are committed to advancing stem cell medicine and finding new cures.From:cordbloodregistryViews:202 7ratingsTime:02:05More inEntertainment

See the article here:
Cord Blood Registry's Leading Science and Research Team - Video

Recommendation and review posted by simmons

Doctor Reviews: Cord Blood Banking and Rapidly Changing Medicine
Learn more about cord blood banking here: http://www.cordblood.com Meet Dr. Michael Chez, Director of Pediatric Neurology and Epilepsy at Sutter Neuroscience Institute in Sacramento, Calif. Dr. Chez has worked first-hand with patients who have undergone cord blood stem cell infusions as potential treatment for conditions like cerebral palsy. "I think we #39;re at the dawn of a very big leap in science with stem cell medicine," he says. According to Dr. Chez, recommending cord blood banking has become fairly standard in prenatal counseling. It #39;s also becoming normal to ask parents if they #39;ve banked when exploring potential treatment options for diseases and disorders that may be treated with cord blood. "Any friend of the family who asks me, I suggest they bank their baby #39;s cord blood," Dr. Chez adds. Cord blood has been successfully used for more than 20 years to treat many serious diseases like certain cancers and blood, immune, and metabolic disorders. Today, clinical trials are investigating new therapies using a child #39;s own cord blood stem cells for conditions that currently have no treatment, like hearing loss, traumatic brain injury, cerebral palsy, and juvenile diabetes. Several of these clinical trials only use stem cells from CBR as a way of ensuring consistent quality, offering CBR clients exclusive access to groundbreaking medicine. You can learn more about CBR #39;s role in advancing stem cell research through our Center for Regenerative Medicine, cordbloodregistry.com Use ...From:cordbloodregistryViews:667 8ratingsTime:01:44More inScience Technology

More here:
Doctor Reviews: Cord Blood Banking and Rapidly Changing Medicine - Video

Recommendation and review posted by simmons

Future Health Biobank Greek video tour
Learn more about the services offered at Future Health: http://www.fhbb.gr Europe #39;s first accredited family stem cell bank and UK Queen #39;s Award winner, Future Health Biobank, is celebrating 10 years as a pioneer in the collection and cryopreservation of stem cells for potential future medical use with the news that it is opening a second laboratory in Switzerland to complement its established UK facility. The company, which is headquartered in Nottingham in the UK, was established to process and store cord blood stem cell samples for families in 2002 at a time when the idea of stem cell medicine was still more likely to be read about in science fiction books than in our daily newspapers and magazines. Future Health started by storing cord blood stem cells in 2003 and within four years it had stored its 10000th sample. Another five years on and the company #39;s purpose built cryogenic storage facility has over 50000 stem cell samples for families from more than 50 countries in its care. A cord tissue storage service was added in 2009 and now services to capture stem cells from other sources identified for potential medical use have been introduced. Future Health have also put time and resources into research. In the last four years the company have invested in a number of important study areas which could have an impact on the future effectiveness and use of stem cells in medical treatments. These include finding the optimum cryopreservation methods which maintain stem cell ...From:FHBioBankViews:206 0ratingsTime:13:05More inScience Technology

Read the original post:
Future Health Biobank Greek video tour - Video

Recommendation and review posted by simmons

Future Health Biobank Arabic video tour
Learn more about the services offered at Future Health: http://www.fhbb.ae Europe #39;s first accredited family stem cell bank and UK Queen #39;s Award winner, Future Health Biobank, is celebrating 10 years as a pioneer in the collection and cryopreservation of stem cells for potential future medical use with the news that it is opening a second laboratory in Switzerland to complement its established UK facility. The company, which is headquartered in Nottingham in the UK, was established to process and store cord blood stem cell samples for families in 2002 at a time when the idea of stem cell medicine was still more likely to be read about in science fiction books than in our daily newspapers and magazines. Future Health started by storing cord blood stem cells in 2003 and within four years it had stored its 10000th sample. Another five years on and the company #39;s purpose built cryogenic storage facility has over 50000 stem cell samples for families from more than 50 countries in its care. A cord tissue storage service was added in 2009 and now services to capture stem cells from other sources identified for potential medical use have been introduced. Future Health have also put time and resources into research. In the last four years the company have invested in a number of important study areas which could have an impact on the future effectiveness and use of stem cells in medical treatments. These include finding the optimum cryopreservation methods which maintain stem cell ...From:FHBioBankViews:140 0ratingsTime:13:05More inScience Technology

Original post:
Future Health Biobank Arabic video tour - Video

Recommendation and review posted by simmons

CBR: Celebrating 20 Years of Advancing Cord Blood Stem Cell Medicine
Learn more about how cord blood is changing medicine here: cordbloodregistry.com Join Cord Blood Registry, the world #39;s largest newborn stem cell bank, in celebrating two decades of offering families more medical options. Cord Blood Registry #39;s story starts in 1992 with the birth of Dr. David Harris #39; son, Alex. The storage of Alex #39;s cord blood stem cells marked the beginning, not only of Cord Blood Registry #39;s lab, but family cord blood banking itself. After 20 years, the first-ever family bank has accomplished many firsts including: bull; First to store cord tissue for families in the United States bull; First and only newborn stem cell bank to have pioneered FDA-regulated clinical trials in regenerative medicine For more than 20 years, cord blood stem cells have been used to help regenerate the blood and immune system in more than 25000 transplants worldwide. Current clinical trials are creating new opportunities to help the body heal itself. For more information on current clinical trial uses, plus the latest research and innovations, visit http://www.cordblood.comFrom:cordbloodregistryViews:227 1ratingsTime:02:55More inScience Technology

Continue reading here:
CBR: Celebrating 20 Years of Advancing Cord Blood Stem Cell Medicine - Video

Recommendation and review posted by simmons

Cord Blood Registry: Cord blood banking for peace of mind
Learn more about how cord blood is changing medicine here: cordbloodregistry.com As an expecting parent today, you have access to a medical resource our parents only dreamed of. Saving or "banking" your newborn #39;s cord blood and cord tissue is a one-time opportunity that may be lifesaving or life-changing for your family. Cord blood stem cells are used to treat many life-threatening diseases, such as leukemia and other cancers. In addition, cord blood is showing potential in research and clinical trials to treat conditions that have no cure today. This exciting new area of medicine is called regenerative medicine, where scientists are evaluating the use of a child #39;s own cord blood stem cells in experimental treatments for brain injury, cerebral palsy, and hearing loss. Only CBR consistently gives our client families first opportunities to participate in new areas of cord blood stem cell medicine. This includes four FDA-regulated clinical trials offered exclusively to CBR clients: bull; Hearing loss bull; Traumatic brain injury bull; Cerebral Palsy bull; Juvenile diabetes You can learn more about CBR #39;s role in advancing stem cell research through our Center for Regenerative Medicine, cordbloodregistry.com Ask your doctor about banking your baby #39;s cord blood with CBR today or call 1-888-932-6568 to speak with a Cord Blood Education Specialist. Use of cord blood stem cells will be determined by the treating physician. There is no guarantee that treatments being studied in the laboratory or ...From:cordbloodregistryViews:400 3ratingsTime:00:16More inPeople Blogs

Here is the original post:
Cord Blood Registry: Cord blood banking for peace of mind - Video

Recommendation and review posted by simmons